Ivanov S V, Syrkin A L, Drobizhev M Iu, Poltavskaia M G, Baturin K A, Burlakov A V
Ter Arkh. 2003;75(10):38-42.
To study efficacy and safety of pirazidol administration in depressive patients with ischemic heart disease (IHD).
Pirazidol was given in a dose 0.15-0.3 g/day for 4 weeks to 30 IHD patients aged 21-65 years. 21 of them had nosogenic depression, 9 patients had dysthymia. The efficacy of the antidepressive action was assessed by the Hamilton scale.
The trend to a decrease in Hamilton scale scores was manifest by the end of the treatment week 2. To the end of the study the overall score median lowered from 17 to 9, most of the patients had the score sum under 11. Side effects were insignificant. In pirazidol combination with beta-blockers, blockers of calcium channels, antiaggregant, diuretic drugs, nitrates and other cardio- and angiotropic drugs unfavorable interactions were not registered.
Pirazidol can be effectively used in the treatment of psychosomatic disorders in patients with cardiovascular diseases.
研究吡拉西多对缺血性心脏病（IHD）伴抑郁患者的疗效及安全性。
对30例年龄在21 - 65岁的IHD患者给予吡拉西多，剂量为0.15 - 0.3克/天，疗程4周。其中21例为心因性抑郁，9例为心境恶劣障碍。采用汉密尔顿量表评估抗抑郁作用的疗效。
治疗第2周末，汉密尔顿量表评分有下降趋势。到研究结束时，总分中位数从17降至9，大多数患者得分总和低于11。副作用不明显。未发现吡拉西多与β受体阻滞剂、钙通道阻滞剂、抗血小板药、利尿剂、硝酸盐及其他心血管和血管活性药物之间存在不良相互作用。
吡拉西多可有效用于治疗心血管疾病患者的心身障碍。
